^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IL2RA-L

    i
    Other names: IL2RA, CD25, IDDM10, IL2R
    Entrez ID:
    3559
    Related biomarkers:
    Expression
    Others
    over1year
    Low CD25 Expression is Associated with Older Age and Poorer Prognosis in Patients with ALK+ Anaplastic Large Cell Lymphoma (USCAP 2023)
    Most cases of ALK+ ALCL highly express CD25 indicating that CD25 is a potential therapeutic target for ALCL patients. In this study, low CD25 expression identified a subset of ALK+ ALCL cases associated with older patient age, thrombocytopenia and shorter OS. These data suggest that assessing CD25 in ALK+ ALCL may be useful for guiding targeted therapy and in predicting prognosis of patients with ALK+ ALCL.
    Clinical
    |
    ALK (Anaplastic lymphoma kinase) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IL2RA (Interleukin 2 receptor, alpha) • CD5 (CD5 Molecule) • CD2 (CD2 Molecule)
    |
    TNFRSF8 expression • IL2RA expression • CD5 positive • IL2R overexpression • IL2RA-L